Purpose: To examine the effects of analgesics on bone mineral density (BMD), which have not been examined in a longitudinal study with multiple measurements.
Opioids have been associated with increased fracture risks in multiple longitudinal studies. [3] [4] [5] [6] [7] [8] The increased risks occurring soon after initiation 4, 6 suggest the primary mechanism is through acute neurologic effects, such as gait imbalance. However, chronic opioid use may also have indirect effects via endocrine changes [9] [10] [11] ; for example, hypogonadotropic hypogonadism has been found in patients receiving methadone maintenance therapy. 12 Several studies also suggest lower BMD in opioid users. [13] [14] [15] However, these studies were cross-sectional, had limited control of confounding, and focused on a particular subset of chronic opioid users (ie, former heroin addicts on methadone maintenance).
NSAID use has been associated with higher BMD in 2 crosssectional studies 16, 17 adjusted for potential confounders such as body weight, although a more recent study found increased fracture risk among NSAID users despite stable BMD. 5 Both selective and non-selective NSAIDs exhibit anti-inflammatory properties through inhibiting cyclooxygenase (COX)-2, an enzyme that plays a role in prostaglandins synthesis. Prostaglandins, in turn, play important roles in both bone formation and bone resorption. 18 The Study of Women's Health Across the Nation (SWAN) 19, 20 allows for rigorous assessment of the effects of analgesics on BMD because of its longitudinal design and repeatedly measured BMD. We hypothesized that opioids and NSAIDs are associated with BMD reduction compared with acetaminophen (active control). Presence of 3 treatment groups of quite different sizes as well as frequent treatment changes posed challenges in analysis. Thus, we used recently proposed matching weights in a multiple group setting 21, 22 along with inverse probability of censoring weights over time. 
| Exposure assessment
The exposure of interest was the type of analgesic-opioid, NSAID including COX-2 selective inhibitors, and/or acetaminophen-that participants took at ≥2 consecutive annual visits. The individual-specific baseline visit was defined as the visit immediately before the first of these consecutive visits. Medication use, including both prescription and over the counter, was ascertained through interviewer-administered questionnaire for medications used twice or more per week during the past month and was then verified by inspection of medication containers.
The exposure definition was constructed hierarchically (eTable 1): opioid user if an opioid is used regardless of the other two; NSAID user if an NSAID is used but not opioids regardless of acetaminophen; and acetaminophen user if it is the only analgesic used. Participants who transitioned between these exposure categories were assigned the exposure status at the time when they first met the eligibility criteria.
| Outcome assessment
Details of the BMD measurements have been described in previous studies using SWAN. [24] [25] [26] BMD (g/cm 2 ) was measured in the lumbar spine and femoral neck at each study visit. Raw BMD measurements were converted to baseline-normalized %BMD values for interpretability, as regularly done in major osteoporosis clinical trials. [27] [28] [29] [30] That is, for each individual, the outcome was defined as 100% at the individual-specific baseline visit when the covariates were ascertained (year 0), and subsequent values were described in relation to this baseline value (eg, 96% of the baseline value at year 4). Follow-up was truncated at year 5 because very few people remained in the initial treatment categories beyond that point.
| Covariate assessment
Covariates were assessed at the individual-specific baseline visit.
Body mass index (BMI) was calculated from height and weight at the study baseline. 
KEY POINTS
• Three-group matching weights are modified propensity score weights that emulate 3-way simultaneous matching.
• Matching weights balanced covariates reasonably across 3 groups with size imbalance.
• We observed a potential decrease in bone mineral density among mid-life women who remained on opioids for 5 years compared with users of acetaminophen.
based on menstrual cycles 25 (eTable 2). We created 4 categories of MT stages for the main analysis: pre-or early perimenopause; late perimenopause; postmenopause; and unknown (eTable 2). We also conducted a subgroup analysis among those who had a known date of the final menstrual period (FMP), using MT stages based on time prior to or after the FMP (eTable 3). 24 
| Statistical analyses
Participant characteristics at the study baseline were summarized within each exposure group. To examine between group imbalance in the unmatched cohort of patients, the standardized mean differences (SMD) 34 were calculated in each pairwise treatment contrast and then averaged across all 3 contrasts. The SMD represents how different groups are for a given covariate. Covariates that have SMD ≤ 0.1 are considered reasonably balanced. 34 We multiply imputed missing covariates via the mice R package. 35, 36 Multinomial logistic regression was used for the propensity score (PS) model because the exposure status had 3 categories (acetaminophen, NSAIDs, or opioids), 37 resulting in 1 PS for each exposure category. All baseline covariates listed in the baseline were incorporated into the model as time-group interaction terms.
We repeated the analyses in the FMP subgroup. We also repeated the main analysis after excluding an outlying data point as a sensitivity analysis. Another sensitivity analysis for the outcome model further adjusted for variables that had SMD > 0.1 after balancing by MW.
3 | RESULTS
| Study population
Among 2365 participants in the SWAN BMD cohort, 71 acetaminophen new users, 659 NSAID new users, and 84 opioid new users were identified (eFigure 1; breakdown by generic names in eTable 4). Their unadjusted baseline characteristics are shown in Table 1 . The most prominent baseline differences were noted for pain-related quality of life, ethnic composition, income, overall perception of health, BMI, femoral neck BMD, and physical activity. The pain-related quality of life was lower for the opioid users (48.8) compared with the other 2 groups that had scores around 70. Femoral neck BMD was higher in the opioid group than the other groups likely associated with their higher BMI. Physical activity was highest among NSAID users and was lowest among opioid users. Twenty-six percent of NSAID users were also exposed to acetaminophen. Opioid users also had substantial concurrent exposure (acetaminophen 80% and NSAIDs 66%). Matching weights reduced group imbalance at the baseline (Table 2) , even in comparison to other PS methods (eFigure 2). 40, 41 The mean follow-up durations were similar across treatment groups (eTable 5).
3.2 | Adjusted main analysis using menstrual perioddefined stages Figure 1 shows the mean baseline-normalized BMD over the 5-year follow-up period for each treatment group (n = 814) as well as the treatment group contrasts from the generalized estimating equation (see eFigure 3 for unadjusted counterpart). The mean annual change in each treatment group as well as group differences in slopes are shown in Table 3 .
The on-treatment analysis ( Figure 1 . 24 The baseline characteristics before PS weighting are in eTable 6. Propensity score weighing improved covariates balance, but to a lesser extent than in the main cohort (eTable 7). The mean trajectories were less stable due to the smaller sample size, particularly in the on-treatment analyses. The mean annual change in each treatment group is shown in eTable 8. The on-treatment analyses exhibited overlapping mean trajectories (eFigure 4, left panels). The initial treatment group analyses (eFigure 4, right panels) produced trajectories with more separation than the main initial treatment group analyses ( Figure 1 , right panels).
| Sensitivity analysis
As the main on-treatment analysis showed a strong fifth-year deflection in the trajectory, we examined for the presence of outliers.
One subject with probable thyroid disease exhibited an outlying decline trajectory. This subject remained in the opioid category for the full 5 years without meeting any of the censoring criteria; thus, she was gradually up-weighted over time via IPCW, becoming more influential. Reanalysis excluding this subject (eFigure 5) resulted in a less prominent decline in the fifth year, although the opioid group remained the lowest group at the fifth year. Outcome analysis further adjusting for the sub-optimally balanced variables gave similar estimates of group differences in slopes (eTable 9).
| DISCUSSION
In the current study, we examined the association between analgesic use and BMD decline over time in a well-established cohort of mid-life women, with a focus on the contrasts between opioids and acetaminophen as well as NSAIDs and acetaminophen. We used 3-group MW for baseline covariate balancing and time-varying IPCW to reduce Abbreviations: APAP, acetaminophen; BMD, bone mineral density in g/cm 2 ; BMI, body mass index; menopausal status, menopausal status defined by menstrual cycles (see eTable 2); NSAID, non-steroidal anti-inflammatory drug; QoL, quality of life; SMD, standardized mean difference. On-treatment analysis censored patients at the time they changed analgesic categories, whereas initial treatment group analysis retained these patients in the initial treatment groups.
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; Ref., reference.
selection bias by artificial censoring over time. To our knowledge, the current study is the first instance of MW used in conjunction with IPCW in the multiple treatment group setting. The average slope differences were not statistically significant in both on-treatment analysis and initial treatment group analysis. However, the on-treatment analysis was suggestive of a potentially greater decline in the BMD in the opioid group compared with the acetaminophen group after 5 years of continuous use. The trajectory of BMD decline in the NSAID group was similar to the acetaminophen group. Between-group differences were not clearly observed in the initial treatment group analysis.
There is no established gold standard for the clinically meaningful group difference in BMD changes over time; however, several clinical trials were summarized in eTable 10 to give some idea. [27] [28] [29] [30] In the dwelling women aged at least 65 years old. 16 Carbone et al 17 examined the cross-sectional association between NSAID use and BMD in the Health ABC study among community-dwelling men and women 70 to 79 years of age. They found that current users of COX-2 selective NSAIDs with concurrent aspirin use had higher BMD than non-users. A 10-year longitudinal study by Vestergaard et al, 5 which also examined acetaminophen, NSAIDs, and opioids, found a very minor (clinically insignificant) increase in spine and whole body BMD among NSAID users compared with non-users. The current study showed essentially identical BMD trajectories between NSAID users and acetaminophen users in both the on-treatment analysis and the initial treatment group analysis.
SWAN was designed to characterize the biological, symptomatic, and psychosocial changes that occur during the menopausal transition and their effects on women's health and well-being. Thus, our findings may not generalize to men, or to women in different age ranges. SWAN did not specifically enroll analgesic users; thus, the number of users was small, limiting our ability to draw firm conclusions. Also, SWAN does not have reliable medication dosage information. Doses of opioids can be highly variable among opioid users due to the highly individualized nature of these prescriptions. 42 However, high-dose opioid use is unlikely in this population cohort of generally healthy mid-life women.
Our longitudinal study design has some unique strengths compared with the prior cross-sectional studies on this topic. Use of acetaminophen as a comparator medication-active comparator design 43 -ensured that all 3 treatment groups had at least some pain.
Non-users-individuals who do not use analgesics-are expected to have much less pain than analgesic users; thus, using such a comparator group without pain could induce a spurious association between BMD changes and medication use, 44 which can be difficult to control for. We also used a new user design, 43 which examines subjects starting the medication of interest, in an attempt to parallel the design of a hypothetical clinical trial 45 and ensures that the baseline covariates were measured before medication initiation.
As a safety outcome study, the primary effect of interest is the on-treatment effect, 39 that is the effect of medication on the outcome if subjects were made to adhere to the regimen. 23 However, the naïve on-treatment analysis that simply censors subjects who do not follow the initial regimen of interest often introduces selection bias. 46 Therefore, we used IPCW to account for selection. The study revealed a difficulty of IPCW in the presence of small number of subjects in each arm. One of the few persistent opioid users happened to have an outlying decline in BMD, thereby exerting increasing influence at later time points because of progressively greater IPCW. Some of the differences in BMD trajectories, however, persisted after excluding this subject. Examination of the very long-term on-treatment effect beyond 5 years was not possible due to the very few adherers, potentially limiting the scope of the study.
In conclusion, the average BMD slope differences over a 5-year period were not statistically significant among mid-life female analgesic new users. However, 5 years of persistent opioid use may be associated with a greater BMD decline. It is important to remember that chronic opioid use, although becoming common, is not a well-justified practice in the setting of non-cancer pain. 47, 48 Further studies examining the relationship between very long-term persistent opioid use and BMD as well as their dose response are warranted.
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